19F-MRS studies of fluorinated drugs in humans

Advanced Drug Delivery Reviews

Volumn 41, Issue 1, 2000, Pages 55-74

  Wolf, Walter ^a   Presant, Cary A ^a   Waluch, Victor ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

5 Fluorouracil; Compartmental modeling; Drug targeting; Pharmacokinetic imaging; Tumor response

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CENTRAL NERVOUS SYSTEM AGENTS; DESFLURANE; ENFLURANE; FLEROXACIN; FLUCYTOSINE; FLUORINE; FLUORINE DERIVATIVE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOXETINE; FLUVOXAMINE; FOLINIC ACID; GEMCITABINE; HALOTHANE; ISOFLURANE; LITHIUM; METHOTREXATE; NEUROLEPTIC AGENT; ORZEL; PRODRUG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEVOFLURANE; TRIMETREXATE; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE;

DRUG HALF LIFE; DRUG METABOLISM; DRUG RESEARCH; DRUG RETENTION; DRUG STRUCTURE; DRUG TARGETING; DRUG TUMOR LEVEL; HUMAN; MEASUREMENT; MODULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; BIOLOGICAL MODEL; METABOLISM; NEOPLASM;

FLUORINE; FLUOROURACIL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, BIOLOGICAL; NEOPLASMS; PRODRUGS;

FLUORINE COMPOUNDS; MAGNETIC RESONANCE IMAGING; MEDICAL IMAGING; METABOLITES; NUCLEAR MAGNETIC RESONANCE; ONCOLOGY;

DRUG TARGETING;

PHARMACOKINETICS;

EID: 0033623840     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00056-3     Document Type: Article

References (136)

1. Shani J., Wolf W. A model of prediction of chemotherapy response to 5-FU in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res. 37:1977;2306-2308.
2. Hanusovska E., Dovinova I., Tkac I., Novotny L. Application of NMR spectroscopy in biochemical studies of tumor cells sensitive and resistant to anticancer drugs. Neoplasma. 45:1998;187-197.
3. Gadian D. NMR and its Applications to Living Systems. 2nd Edition :1996;Oxford University Press, New York.
4. Daly P.F., Cohen J.S. Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review. Cancer Res. 49:1989;770-779.
5. 19F MRS studies of fluoropyrimidine chemotherapy: a review. NMR Biomed. 2:1989;133-141.
6. Malet-Martino M.C., Martino R., Armand J.P. Fluorine-19 nuclear magnetic resonance spectroscopy: a privileged tool for the study of the metabolism and pharmacokinetics of fluoropyrimidines. Bull. Cancer (Paris). 77:1990;1223-1244.
7. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 5:1992;303-324.
8. 19F NMR of perfluorocarbons. Artif. Cells Blood Subst. Immobil. Biotechnol. 22:1994;1141-1153.
9. 19F NMR in Medicine. Fluorine in Medicine in the 21st Century. 13:1994;1-13 University of Manchester.
10. Passe T.J., Charles H.C., Rajagopalan P., Krishnan K.R. Nuclear magnetic resonance spectroscopy: a review of neuropsychiatric applications. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;541-563.
11. Van Den Thillart G., Van Waarde A. Nuclear magnetic resonance spectroscopy of living systems: applications in comparative physiology. Phys. Rev. 76:1996;799-837.
12. Soares J.C., Krishnan K.R., Keshavan M.S. Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders. Depression. 4:1996;14-30.
13. Robinson S.P., Barton S.J., McSheehy P.M., Griffiths J.R. Nuclear magnetic resonance spectroscopy of cancer. Br. J. Radiol. 70:1997;S60-S69.
14. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer. 80:1997;1179-1187.
15. Wolf W. Imaging can be much more than pretty pictures. Pharm. Sci. 12:1995;1821-1822.
16. Duschinsky R., Pleven E., Heidelberger C. The synthesis of 5-fluoropyrimidines. J. Am. Chem. Soc. 79:1957;4559-4560.
17. Heidelberger C. Biochemical approaches to new cancer chemotherapeutic agents. Proc. Natl. Cancer Conf. 6:1970;599-604.
18. Heidelberger C. The nucleotides of fluorinated pyrimidines and their biological activities. Ciba Found. Symp. 2:1971;125-140.
19. Heidelberger C. On the rational development of a new drug: the example of the fluorinated pyrimidines. Cancer Treat. Repts. 65:(Suppl 3):1981;3-9.
20. Spears C.P., Shahinian A.H., Moran R.G., Heidelberger C., Corbett T.H. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res. 42:1982;450-456.
21. Heidelberger C., Danenberg P.V., Moran R.G. Fluorinated pyrimidines and their nucleosides. Adv. Enzymol. Relat. Areas Mol. Biol. 54:1983;58-119.
22. Spears C.P., Shani J., Shahinian A.H., Wolf W., Heidelberger C., Danenberg P.V. Assay and time course of 5-fluorouracil incorporation into RNA of L1210/0 ascites cells in vivo. Mol. Pharmacol. 27:1985;302-307.
23. Harstrick A., Gonzales A., Schleucher N., Vanhoefer U., Lu K., Formento J.L., Milano G., Wilke H., Seeber S., Rustum Y. Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance. Anticancer Drugs. 9:1998;625-634.
24. Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology. 12:1998;19-22.
25. Ghoshal K., Jacob S.T. An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem. Pharmacol. 53:1997;1569-1575.
26. Parker W.B., Cheng Y.C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 48:1990;381-395.
27. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16:1989;215-237.
28. Pinedo H.M., Peters G.F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6:1988;1653-1664.
29. Metzger R., Danenberg K., Leichman C.G., Salonga D., Schwartz E.L., Wadler S., Lenz H.J., Groshen S., Leichman L., Danenberg P.V. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res. 4:1998;2371-2376.
30. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55:1995;1407-1412.
31. Roos G., Stenram U. Incorporation of 5-fluorouracil into hepatoma and normal tissue RNA at protein depletion in the rat. J. Surg. Oncol. 65:1997;155-158.
32. Ren Q., Van Groeningen C.J., Hardcastle A., Aherne G.W., Geoffroy F., Allegra C.J., Johnston P.G., Grem J.L. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells. Oncol. Res. 9:1997;77-88.
33. Fraile R.J., Baker L.H., Buroker T.R., Horwitz J., Vaitkevicius V.K. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous bolus and by slow infusion. Cancer Res. 40:1980;2223-2228.
34. MacMillan W.E., Wolberg W.H., Welling P.G. Pharmacokinetics of fluorouracil in humans. Cancer Res. 38:1978;3479-3482.
35. 19F nuclear magnetic resonance spectroscopy. Cancer Res. 59:1999;122-127.
36. Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology. 12:1998;19-22.
37. 19F NMR study. Cancer Chem. Pharmacol. 42:1998;341-344.
38. Blesing C.H., Kerr D.J. Intra-hepatic arterial drug delivery. J. Drug Target. 3:1996;341-347.
39. Kamm Y.J., Wagener D.J., Rietjens I.M., Punt C.J. 5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules. Anticancer Drugs. 9:1998;371-380.
40. Grem J.L. Recent insights into the molecular basis of intrinsic resistance of colorectal cancer: new challenges for systemic therapeutic approaches. Cancer Treat. Res. 98:1998;293-338.
41. O'Dwyer P.J., Stevenson J.P. Chemotherapy of advanced colorectal cancer. Cancer Treat. Res. 98:1998;111-152.
42. Punt C.J. New drugs in the treatment of colorectal carcinoma. Cancer. 83:1998;679-689.
43. van Laar J.A., Rustum Y.M., Ackland S.P., van Groeningen C.J., Peters G.J. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur. J. Cancer. 34:1998;296-306.
44. Shanahan F., O'Sullivan G.C. Progress in treating esophageal adenocarcinoma. Gastroenterology. 112:1997;1417-1418.
45. Kelsen D.P., Ilson D.H. Chemotherapy and combined-modality therapy for esophageal cancer. Chest. 107:1995;224S-232S.
46. Vincent M., Labianca R., Harper P. Which 5-fluorouracil regimen? - the great debate. Anticancer Drugs. 10:1999;337-354.
47. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer. 80:1997;1179-1187.
48. Rustum Y.M., Harstrick A., Cao S., Vanhoefer U., Yin M.B., Wilke H., Seeber S. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. 15:1997;389-400.
49. Labianca R., Pessi A., Facendola G., Pirovano M., Luporini G. Modulated 5-fluorouracil (5-FU] regimens in advanced colorectal cancer: a critical review of comparative studies. Eur. J. Cancer. 32A:(Suppl 5):1996;S7-S12.
50. Balaban E.P., Graham M., Perkins S., Sheehan R.G., Frenkel E.P., Ross M., Bull J., Pruitt B., Periman P., Ruud C. Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. Cancer Invest. 12:1994;12-19.
51. Wils J.A. High-dose fluorouracil: a new perspective in the treatment of colorectal cancer? Semin. Oncol. 19:(2 Suppl 3):1992;126-130.
52. Bertino J.R. Biomodulation of 5-fluorouracil with antifolates. Semin. Oncol. 24:(S18):1997;52-56.
53. Blanke C.D., Kasimis B., Schein P., Capizzi R., Kurman M. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J. Clin. Oncol. 15:1997;915-920.
54. Martin D.S. Biochemical modulation of 5-fluorouracil by PALA: mechanism of action. Adv. Exp. Med. Biol. 339:1993;153-163.
55. van der Wilt C.L., Smid K., Aherne G.W., Noordhuis P., Peters G.J. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur. J. Cancer. 33:1997;471-478.
56. Van Cutsem E., Peeters M., Verslype C., Filez L., Haustermans K., Janssens J. The medical treatment of colorectal cancer: actual status and new developments. Hepato-Gastroenterology. 46:1999;709-716.
57. Fornier M., Munster P., Seidman A.D. Update on the management of advanced breast cancer. Oncology. 13:1999;647-658. discussion 660, 663-664.
58. Blum J.L., Jones S.E., Buzdar A.U., LoRusso P.M., Kuter I., Vogel C., Osterwalder B., Burger H.U., Brown C.S., Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17:1999;485-493.
59. Pazdur R., Hoff P.M., Medgyesy D., Royce M., Brito R. The oral fluorouracil prodrugs. Oncology. 12:(Suppl 7):1998;48-51.
60. Bunnell C.A., Winer E.P. Oral 5-FU analogues in the treatment of breast cancer. Oncology. 12:(10 Suppl 7):1998;39-43.
61. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., Shimma N., Umeda I., Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer. 34:1998;1274-1281.
62. Takiuchi H., Ajani J.A. Uracil-tegafur in gastric carcinoma: a comprehensive review. J. Clin. Oncol. 16:1998;2877-2885.
63. Hirata K., Horikoshi N., Aiba K., Okazaki M., Denno R., Sasaki K., Nakano Y., Ishizuka H., Yamada Y., Uno S., Taguchi T., Shirasaka T. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin. Cancer Res. 5:1999;2000-2005.
64. Menei P., Venier M.C., Gamelin E., Saint-Andre J.P., Hayek G., Jadaud E., Fournier D., Mercier P., Guy G., Benoit J.P. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma. A pilot study. Cancer. 86:1999;325-330.
65. Brem H., Lawson H.C. The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers. Cancer. 86:1999;197-199.
66. 18F-5-fluorouracil. Int. J. Appl. Radiat. Isotop. 30:1979;401-405.
67. 18F-5-fluorouracil in tumor bearing mice and rats. Int. J. Nucl. Med. Biol. 5:1978;19-28.
68. Young D., Vine E., Ghanbarpour A., Shani J., Siemsen J.K., Wolf W. Metabolic and distribution studies with radiolabeled 5-fluorouracil. Nucl. Med. 21:1982;1-7.
69. 18F-5FU. Int. J. Nucl. Med. Biol. 9:1982;25-35.
70. Lauterbur P.C. Image formation by induced local interactions: examples employing nuclear magnetic resonance. Nature. 241:1973;190.
71. Damadian R. Field focusing NMR (FONAR] and the formation of chemical images in man. Phil. Trans. Royal Soc. 289:1980;489.
72. 19F Magnetic resonance imaging. J. Magn. Reson. 28:1977;133.
73. Malet-Martino M.C., Martino R., Lopez A., Beteille J.P., Bon M., Bernadou J., Armand J.P. New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine-19 NMR. Cancer Chemother. Pharmacol. 13:1984;31-35.
74. Malet-Martino M.C., Faure F., Vialaneix J.P., Palevody C., Hollande E., Martino R. Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. Cancer Chem. Pharmacol. 18:1986;5-10.
75. 19F NMR. Br. J. Cancer. 50:1984;113-117.
76. Wolf W., Griffiths J.R., Silver M., Bruckner H. Can NMR contribute to the radiopharmacokinetics of 5-fluorouracil in man? J. Nucl. Med. 27:1986;737.
77. Wolf W., Albright M.J., Silver M.S., Weber H., Reichardt U., Sauer R. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn. Reson. Imaging. 5:1987;165-169.
78. 19F-NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl. Acad. Sci. USA. 87:1990;492-496.
79. 19F nuclear magnetic resonance study. Lancet. 343:1994;1184-1187.
80. 19F magnetic resonance spectroscopy predicts clinical 5-FU sensitivity and resistance. Banzet P., Holland J.F., Khanat D., Weil M. Cancer Treatment, an Update. 1994;757-758 Springer Verlag, New York.
81. Wolf W., Waluch V., Presant C.A., Kim H.K., Sancho A.R. Pharmacokinetic imaging of 5-fluorouracil in tumors using 19F-NMR spectroscopy. Eurospin Annual. 1995-1996;99-103.
82. Presant C.A., Wolf W., Waluch V. What determines that 5-FU is active against tumors? Ann. Oncol. 8:1997;203-204.
83. 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed. 11:1998;380-387.
84. 19F-magnetic resonance spectroscopy. J. Clin. Oncol. (1999) in press.
85. Schlemmer H.P., Becker M., Bachert P., Dietz A., Rudat V., Vanselow B., Wollensack P., Zuna I., Knopp M. V, Weidauer H., Wannenmacher M., van Kaick G. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res. 59:1999;2363-2369.
86. 19F MR imaging. Magn. Reson. Imaging. 17:1999;151-155.
87. Bachert P. Pharmacokinetics using fluorine NMR in vivo. Prog. NMR Spectroscopy. 33:1998;1-56.
88. 19F spectroscopy of 5-FU catabolites in human liver. Magn. Reson. Med. 37:1997;321-326.
89. 19F magnetic resonance spectroscopy. Clin. Cancer Res. 2:1996;339-345.
90. 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-alpha. Ann. Oncol. 7:1996;47-53.
91. 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. Magn. Reson. Imaging. 12:1994;497-511.
92. Findlay M.P.N., Leach M.O., Cunningham D., Collins D.J., Paynes G.S., Glaholm M.J., Mansi J.L., McCready V.R. The noninvasive monitoring of low-dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo F-19 magnetic resonance spectroscopy in patients with colorectal cancer. A pilot study. Ann. Oncol. 4:1993;597-602.
93. 19F magnetic resonance spectroscopy. Br. J. Radiol. 63:1990;547-553.
94. Semmler W., Bachert-Baumann P., Guckel F., Ermark F., Lorenz W.J., van Kaick G. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology. 174:1990;141-145.
95. Weiss M. Pharmacokinetics in organs and the intact body: model validation and reduction. Eur. J. Pharm. Sci. 7:1999;119-127.
96. Vallabhajosula S.R., Harwig J.F., Wolf W. The mechanism of tumor localization of gallium-67 citrate: role of transferrin binding and effect of tumor pH. Int. J. Nucl. Med. 8:1981;363-370.
97. 19F nuclear magnetic resonance spectroscopy. Cancer Res. 51:1991;5770-5773.
98. 31P MRS as a method of measuring pH in rat tumours. NMR Biomed. 5:1992;351-359.
99. 19F NMR spectroscopy. Eurospin Annual. 1995-1996;92-98.
100. 1H] nuclear Overhauser effect and proton decoupling of 5-fluorouracil and alpha-fluoro-beta-alanine. J. Magn. Reson. B. 108:1995;155-164.
101. Doyle V.L., Buil M., Payne G.S., Leach M.O. Calculations of sensitivity correction factors for surface coil MRS. Magn. Reson. Med. 33:1995;108-112.
102. Andersen M.E., Krewski D., Withey J.R. Physiological pharmacokinetics and cancer risk assessment. Cancer Lett. 69:1993;1-14.
103. Gibaldi M., Koup J.R. Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance. Eur. J. Clin. Pharmacol. 20:1981;299-305.
104. Peters G.J., Lankelma J., Kok R.M., Noordhuis P., van Groeningen C.J., van der Wilt C.L., Meyer S., Pinedo H.M. Long retention of high concentrations of 5-fluorouracil in human and murine tumors compared to plasma. Cancer Chemother. Pharmacol. 31:1993;269-272.
105. Wohlhueter R.M., McIvor R.S., Plagemann P.G.W. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J. Cell. Physiol. 104:1980;309-319.
106. Yamamoto S., Kawasaki T. Active transport of 5-fluorouracil and its energy coupling in Ehrlich ascites tumor cells. J. Biochem. 90:1981;635-642.
107. Yuasa H., Matsuhisa E., Watanabe J. Intestinal brush border transport mechanism of 5-fluorouracil in rats. Biol. Pharm. Bull. 19:1996;94-99.
108. Ojugo A.S., McSheehy P.M., Stubbs M., Alder G., Bashford C.L., Maxwell R.J., Leach M.O., Judson I.R., Griffiths J.R. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br. J. Cancer. 77:1998;873-879.
109. 18F-5-fluorouracil in tumor bearing mice and rats. Int. J. Nucl. Med. Biol. 5:1978;19-28.
110. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Microcirculation. 4:1997;1-23.
111. Fukumura D., Yuan F., Monsky W.L., Chen Y., Jain R.K. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am. J. Pathol. 151:1997;679-688.
112. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA. 95:1998;4607-4612.
113. Sancho A.R., Kim H.K., Wolf W. Noninvasive studies of tumor pathophysiology: heterogeneity changes as a function of tumor size. Proc. Am. Assoc. Cancer Res. 39:1998;1003.
114. 19F-nuclear magnetic resonance spectroscopy. Cancer Res. 51:1991;5806-5812.
115. 19F-MRS study in vivo. Br. J. Cancer. 65:1992;369-375.
116. Kim H.K., Waluch V., Presant C.A., Wolf W. Noninvasive measurement of drug targeting to tumors using MR contrast agents as surrogate tracers. Proc. Am. Assoc. Cancer Res. 38:1998;2225.
117. Leichman C.G., Lenz H.J., Leichman L., Danenberg K.D., Baranda J., Groshen S., Boswell W., Metzger R., Tan M., Danenberg P.V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15:1997;3223-3229.
118. Lenz H.-J., Leichman C.G., Danenberg K.D., Danenberg P.V., Groshen S., Cohen H., Laine L., Crookes P., Silberman H., Baranda J., Garcia Y., Li J., Leichman L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol. 14:1996;176-182.
119. Leichman L., Lenz H.-J., Leichman C.G., Groshen S., Danenberg K., Baranda J., Spears C.P., Boswell W., Silberman H., Ortega A., Stain S., Beart R., Danenberg P.V. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur. J. Cancer. 31A:1995;1306-1310.
120. Haberkorn U., Oberdorfer F., Gebert J., Morr I., Haack K., Weber K., Lindauer M., van Kaick G., Schackert H.K. Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine. J. Nucl. Med. 37:1996;87-94.
121. Lawrence T.S., Rehemtulla A., Ng E.Y., Wilson M., Trosko J.E., Stetson P.L. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res. 58:1998;2588-2593.
122. Aboagye E.O., Artemov D., Senter P.D., Bhujwalla Z.M. Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. Cancer Res. 58:1998;4075-4078.
123. 19F-magnetic resonance spectroscopy (MRS). Proc. Am. Assoc. Cancer Res. 40:1999;3170.
124. Hertel L.W., Boder G.B., Kroin J.S., Rinzel S.M., Poore G.A., Todd G.C., Grindey J.B. Evaluation of the antitumor activity of gemcitabine (2′2′difluorodeoxycytidine). Cancer Res. 50:1990;4417-4422.
125. 19F magnetic resonance spectroscopy (MRS) and correlation with tumor blood flow/perfusion (TBF) measured by dynamic enhanced MRI (DEMRI). Proc. Am. Soc. Clin. Oncol. 18:1999;756.
126. 19F-NMR study of isoflurane elimination from brain. Biochim. Biophys. Acta. 927:1987;86-91.
127. 19F NMR technique. Magn. Reson. Med. 9:1989;219-228.
128. Litt L., Gonzalez-Mendez R., James T.L., Sessler D.I., Mills P., Chew W., Moseley M., Pereira B., Severinghaus J.W., Hamilton W.K. An in vivo study of halothane uptake and elimination in the rat brain with fluorine nuclear magnetic resonance spectroscopy. Anesthesiology. 67:1987;161-168.
129. 19F chemical shift imaging. Magn. Reson. Med. 35:1996;626-630.
130. Kato T., Inubushi T., Kato N. Magnetic resonance spectroscopy in affective disorders. J. Neuropsychiatry Clin. Neurosci. 10:1998;133-147.
131. Strauss W.L., Layton M.E., Dager S.R. Characterization of human brain pharmacokinetics using a two-compartment model. Biol. Psychiatry. 45:1999;1384-1388.
132. 19F magnetic resonance spectroscopy. Am. J. Psychiatry. 155:1998;380-384.
133. 19F Magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am. J. Psychiatry. 154:1997;516-522.
134. 19F spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn. Reson. Med. 31:1994;204-211.
135. Jynge P., Skjetne T., Gribbestad I., Kleinbloesem C.H., Hoogkamer H.F., Antonsen O., Krane J., Bakoy O.E., Furuheim K.M., Nilsen O.G. In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. Clin. Pharmacol. Ther. 48:1990;481-489.
136. Aboagye E.O., Kelson A.B., Tracy M., Workman P. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anti-Cancer Drug Des. 13:1998;703-730.